Anthropic details early drug-development work using Claude
Anthropic said it has expanded its life-sciences work across six outside drug-development partnerships and internal programs, offering early evidence of how Claude is being used in preclinical research, manufacturing review and trial planning. The Oct. 27, 2026 update describes early-stage results rather than clinical proof, and says the work is intended to scale further.
Evidence and context
In the company’s account, its life sciences team has worked over the past several months with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, while also starting drug-discovery programs of its own, including efforts focused on rare childhood muscular dystrophies. Anthropic said the projects are meant to show how Claude can support multiple steps in drug development, from early target research and molecule design to manufacturing documentation, regulatory drafting and clinical-trial planning.
The strongest claims in the update are still preclinical and vendor-reported. Anthropic said Generate Biomedicines used Claude Code to propose a shorter genetic design for a CAR T-cell therapy component, with one design about 70% shorter than the standard version and associated with roughly 10 times as many receptors in lab tests, more efficient tumor-cell killing and longer immune-cell activity. At Divergence Labs, Anthropic said Claude helped generate roughly 35,000 antibody designs in about a month, yielding three designs that could bind IgE and 20 that could dislodge it; three of the 20 appeared to dislodge IgE more than the standard medication.
Anthropic also said BigHat Biosciences and an Anthropic researcher used Claude with lab data systems to improve two antibody fragments, with the best versions binding more than 10 times more tightly, one staying in solution 18°C higher and the other clumping more than 100 times more slowly. At Enveda, Anthropic said Claude reviewed 1,061 pages of manufacturing documentation, catching all 11 issues found by human reviewers and seven more they missed, reducing human review time by 89% from more than 25 hours to less than three. The company also said Claude drafted two regulatory documents, one in four hours versus about three months by hand.
Anthropic further said The Column Group is building a new company, Pleiades, to use Claude across more and more complex drug programs, and that its first Claude skill for assessing drug targets has been evaluated on 45 target-disease pairs. In a separate partnership with Bristol Myers Squibb, the company said Claude is being used to assess an early-stage drug trial plan and estimate the likelihood of success; a quoted BMS executive said the model generated an initial analysis from a single prompt that would otherwise take days. Anthropic said it plans to expand that work in 2027.
The company also said it acquired Mithril Medicine, a one-person company working on rare muscular dystrophies, and that its founder used Claude to organize contracts, logistics and experiments with 11 external labs. Anthropic said one program moved from idea to promising mouse results in less than 18 months, and that, if the candidates continue to hold up, a drug could be ready to start human trials as soon as late 2028. That timing remains contingent on continued preclinical progress.
Limits and next steps
Anthropic said the research is still early and mostly preclinical, with human testing not yet underway in most cases. It also framed the results as a way to improve Claude itself, saying the programs have already prompted model improvements and may help identify bottlenecks across the drug-development process. The company cited related recent steps including an Oct. 22, 2026 open call for guest investigators in the life sciences and a Sept. 17, 2026 launch of the Life Sciences Verification Program, alongside earlier product releases for Claude for Life Sciences and Claude Science.